Arbutus to Present Preclinical HBV Data at EASL 2016

Wednesday, March 30, 2016 5:35 PM UTC

VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 30, 2016 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted an abstract for presentation at the EASL 2016 annual meeting to be held April 13 - 17, 2016, in Barcelona, Spain.

“We are pleased to present data on our core protein/capsid assembly inhibitor program, which supports our strategy of attacking HBV through multiple different mechanisms of action,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “Our lead HBV product candidate, ARB-1467, is in an ongoing Phase II study in chronically infected HBV patients. In addition, we are advancing our other HBV programs to support initiation of clinical combination studies in 2017.”

Poster Presentation

Title: "In Vitro and In Vivo Antiviral Activities of AB-423 a Potent Small Molecule Inhibitor of Hepatitis B Virus Capsid Assembly”
Date: Thursday, April 14, 2016
Abstract Number: THU-198

About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.

Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: [email protected]

Helia Baradarani
Manager, Investor Relations
Phone: 604.419.3200
Email: [email protected]

Media
Please direct all media inquiries to: [email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Arbutus to Present Preclinical HBV Data at EASL 2016

Editor's Picks

Welcome to EconoTimes